Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock

Home/Newsroom/

Arrowhead Pharmaceuticals Announces...

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the

pricing of an underwritten public offering of 10,000,000 shares of its

common stock, offered at a price of $5.25 per share, before underwriting

discounts. The offering is expected to close on or about January 22,

2018, subject to customary closing conditions. In addition, Arrowhead

has granted the underwriters of the offering a 30-day option to purchase

up to an additional 1,500,000 shares of common stock at the public

offering price, less the underwriting discount. Jefferies LLC and

Barclays Capital Inc. are acting as bookrunning managers for the

offering, Cantor Fitzgerald & Co. is acting as passive joint bookrunner

for the offering and Chardan and B. Riley FBR, Inc. are acting as

co-managers for the offering.

Gross offering proceeds will be approximately $52.5 million, before

deducting underwriting discounts and commissions and offering expenses.

Arrowhead intends to use the net proceeds from this offering for general

corporate purposes, including working capital, capital expenditures,

research and development expenditures and clinical trial expenditures. A

portion of the net proceeds may also be used for the acquisition of

complementary businesses, products and technologies, or for other

strategic purposes.

A shelf registration statement on Form S-3 (File No. 333-214315)

relating to the public offering of the shares of common stock described

above was filed with the Securities and Exchange Commission (the “SEC”)

and is effective. A final prospectus supplement relating to the offering

will be filed with the SEC and will be available on the SEC’s web site

at www.sec.gov.

When available, copies of the final prospectus supplement may also be

obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus

Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by

telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com

or from Barclays Capital Inc., Attention: Broadridge Financial

Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone:

1-888-603-5847, or email: Barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or the

solicitation of an offer to buy these securities, nor shall there be any

sale of these securities in any jurisdiction in which such offer,

solicitation or sale would be unlawful prior to the registration or

qualification under the securities laws of any such jurisdiction.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable

diseases by silencing the genes that cause them. Using a broad portfolio

of RNA chemistries and efficient modes of delivery, Arrowhead therapies

trigger the RNA interference mechanism to induce rapid, deep, and

durable knockdown of target genes. RNA interference, or RNAi, is a

mechanism present in living cells that inhibits the expression of a

specific gene, thereby affecting the production of a specific protein.

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of

gene silencing.

Safe Harbor Statement under the Private Securities Litigation Reform

Act:

This news release contains forward-looking statements within the

meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. Such forward-looking statements include

statements regarding our expectations with respect to our proposed

public offering. These statements are based upon our current

expectations and speak only as of the date hereof. Our actual

results may differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors and

uncertainties, including, without limitation, risks and uncertainties

associated with market conditions and the satisfaction of customary

closing conditions related to the proposed offering. Our Annual

Report on Form 10-K, recent and forthcoming Quarterly Reports on Form

10-Q, recent Current Reports on Forms 8-K, and other SEC filings discuss

some of the important risk factors that may affect our ability to

achieve the anticipated results, as well as our business, results of

operations and financial condition. Readers are cautioned not to place

undue reliance on these forward-looking statements. Additionally,

Arrowhead disclaims any intent to update these forward-looking

statements to reflect subsequent developments.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors

and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com

Source: Arrowhead Pharmaceuticals, Inc.

News Provided by Acquire Media